Format

Send to

Choose Destination
Mayo Clin Proc. 2002 Nov;77(11):1159-63.

Pilot evaluation of gabapentin for treating hot flashes.

Author information

1
Division of Medical Oncology, Mayo Clinic, Rochester, Minn 55905, USA. cloprinzi@mayo.edu

Abstract

OBJECTIVE:

To obtain pilot prospective data regarding the efficacy and tolerability of gabapentin for alleviating hot flashes.

PATIENTS AND METHODS:

This prospective single-arm clinical trial was conducted between July 26, 2001, and November 30, 2001. Patients underwent a baseline week and then 4 weeks of gabapentin treatment, with increasing doses during the first 3 weeks, from 300 to 600 to 900 mg/d. Data were obtained primarily from patient-completed questionnaires.

RESULTS:

Data from 20 evaluable women (of 24 entered in the trial) were available. Four patients discontinued use of gabapentin for perceived drug-related untoward symptoms, primarily related to light-headedness and dizziness. The 16 patients who completed this clinical trial had a mean reduction in hot flash frequency, in the fourth treatment week compared to the baseline week, of 66%. Their corresponding hot flash score (frequency times average severity) reduction was 70%. Additionally, patients who completed the 4 treatment weeks had a strong tendency to report an improvement in several other symptoms.

CONCLUSION:

Although a double-blind placebo-controlled clinical trial should be conducted to better elucidate the efficacy and toxicity of gabapentin in patients with hot flashes, the available data suggest that gabapentin is a reasonable treatment to consider in patients with hot flashes if they do not wish to use hormonal therapy.

PMID:
12440550
DOI:
10.4065/77.11.1159
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center